| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Xiao Ran, Tingting Xu, Hang Ruan, Xiaochuan Wang, Qin Zhan. Tissue Kallikrein Supplementation in Ischemic Phase Protects the Neurovascular Unit and Attenuates Reperfusion-Induced Injury in Ischemic Stroke. Pharmacological research. 2024-09-30. PMID:39349214. |
tissue kallikrein (tk) has emerged as a potential neuroprotective agent in ischemic stroke (is), yet the optimal timing and mechanisms of tk therapy remain unclear. |
2024-09-30 |
2024-10-03 |
human |
| Xiao Ran, Dao Wen Wang, Zhen Yu, Rongxue Wu, Qin Zhan. Decreased Tissue Kallikrein Levels and the Risk of Ischemic Stroke: A Community-Based Cross-Sectional Study in China. Journal of inflammation research. vol 15. 2022-01-13. PMID:35023947. |
changes in tk level in plasma are associated with ischemic stroke and coronary artery disease (cad); however, a causal correlation could not be established. |
2022-01-13 |
2023-08-13 |
Not clear |
| Jiawei Yang, Jianhua Su, Fen Wan, Nan Yang, Haibo Jiang, Mingming Fang, Hang Xiao, Jun Wang, Jinrong Tan. Tissue kallikrein protects against ischemic stroke by suppressing TLR4/NF-κB and activating Nrf2 signaling pathway in rats. Experimental and therapeutic medicine. vol 14. issue 2. 2020-09-30. PMID:28810574. |
therefore, tk may provide an effective intervention with a wider therapeutic window for ischemic stroke. |
2020-09-30 |
2023-08-13 |
rat |
| Jiawei Yang, Jianhua Su, Fen Wan, Nan Yang, Haibo Jiang, Mingming Fang, Hang Xiao, Jun Wang, Jinrong Tan. Tissue kallikrein protects against ischemic stroke by suppressing TLR4/NF-κB and activating Nrf2 signaling pathway in rats. Experimental and therapeutic medicine. vol 14. issue 2. 2020-09-30. PMID:28810574. |
tissue kallikrein (tk) has been proven to elicit a variety of biological effects in ischemic stroke through its anti-inflammatory and anti-oxidant properties. |
2020-09-30 |
2023-08-13 |
rat |
| Fei Wu, Yifeng Ling, Lumeng Yang, Xin Cheng, Qiang Dong, Wenjie Ca. High Level of Serum Tissue Kallikrein Is Associated with Favorable Outcome in Acute Ischemic Stroke Patients. Disease markers. vol 2019. 2019-12-10. PMID:31275448. |
we sought to assess the association between a serum tissue kallikrein (tk) level and a 90-day outcome in acute ischemic stroke (ais) patients who received acute reperfusion therapy. |
2019-12-10 |
2023-08-13 |
Not clear |
| Ling Liu, Renliang Zhang, Kui Liu, Houguang Zhou, Yuping Tang, Jinjin Su, Xiaoyan Yu, Xuelian Yang, Min Tang, Qiang Don. Tissue kallikrein alleviates glutamate-induced neurotoxicity by activating ERK1. Journal of neuroscience research. vol 87. issue 16. 2010-01-05. PMID:19598250. |
thus, tk represents a promising therapeutic strategy for ischemic stroke. |
2010-01-05 |
2023-08-12 |
human |
| Ling Liu, Renliang Zhang, Kui Liu, Houguang Zhou, Xuelian Yang, Xinfeng Liu, Min Tang, Jinjin Su, Qiang Don. Tissue kallikrein protects cortical neurons against in vitro ischemia-acidosis/reperfusion-induced injury through the ERK1/2 pathway. Experimental neurology. vol 219. issue 2. 2009-09-29. PMID:19576887. |
therefore, tk represents a promising therapeutic strategy for ischemic stroke. |
2009-09-29 |
2023-08-12 |
human |